Physician profile
Wenge Wang
NPI 1497047195
$6,435.09
in general payments reported to CMS, 2019-2025
17 companies · $983 in 2025
The $983 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $229 · 2020: $1,817 · 2021: $2,031 · 2022: $370 · 2023: $291 · 2024: $714 · 2025: $983.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,221 · Travel and Lodging: $731 · Education: $35.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,221.11 |
| Travel and Lodging | $730.90 |
| Education | $35.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Clovis Oncology, INC. | $1,777.49 | 2019-2020 | |
| Eisai INC. | $1,661.35 | 2019-2024 | |
| Abbvie INC. | $950.22 | 2024-2025 | |
| Glaxosmithkline, LLC. | $730.25 | 2020-2024 | Jemperli, Zejula |
| Astrazeneca Pharmaceuticals LP | $711.90 | 2019-2025 | Enhertu, Imfinzi, Lynparza |
| Gilead Sciences, INC. | $117.84 | 2024 | Vemlidy |
| Immunogen, INC. | $107.74 | 2023 | Elahere |
| Merck Sharp & Dohme LLC | $93.91 | 2023-2024 | Keytruda, Lynparza |
| Regeneron Pharmaceuticals, INC. | $66.58 | 2022-2025 | |
| Pfizer INC. | $54.85 | 2024 | |
| Novartis Pharmaceuticals Corporation | $53.99 | 2024 | |
| Seagen INC. | $43.37 | 2022 | |
| Puma Biotechnology, INC. | $27.10 | 2024 | |
| Lilly USA, LLC | $19.73 | 2024 | Verzenio |
| Tesaro, INC. | $18.77 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wenge Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.